Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004143 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
A Phase 2 study, sponsored by David Rizzieri, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00004143 is a Phase 2 study that has completed, run by David Rizzieri, MD. The registered enrollment target is 2 participants.
The verdict
NCT00004143, a Phase 2 study, has completed, sponsored by David Rizzieri, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood. Unfortunately, the conventional approach to allogeneic stem cell transplantation is a risky procedure. For some non-cancerous conditions, the risks of this procedure outweigh the potential benefits. This protocol is designed to test a new approach to allogeneic stem cell transplantation. It is hoped that this approach will be better suited for patients with non-cancerous blood and bone marrow disorders.
Interventions
- DRUG Campath, Chemo and/or TBI Allo SCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 1999-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004143
The ClinicalTrials.gov registry entry for NCT00004143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Rizzieri, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Campath, Chemo and/or TBI Allo SCT is the first listed.
NCT00004143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004143 about?
NCT00004143 is a clinical study titled "Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes". RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood. Unfortunately, the conventional approach to allogeneic stem cell transplantation is a risky proce...
What is the current status of trial NCT00004143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 1999-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00004143?
The interventions under investigation include: Campath, Chemo and/or TBI Allo SCT (DRUG).
Who is sponsoring clinical trial NCT00004143?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.